Study of GB261 for refractory lupus
Part of Immune system & allergy, Skin clinical trials.
This study tests a new drug called GB261 in people with active systemic lupus erythematosus (SLE) that hasn't improved with standard treatments. It aims to see if the drug is safe and effective in reducing lupus activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of SLE.
- You must test positive for certain antibodies (anti-dsDNA, anti-Smith, or ANA).
- Your lupus must be active and not responding to standard treatments.
- You must be on a stable dose of your current medications.
- If you have lupus nephritis, you must have a kidney biopsy showing class III or IV disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
This trial tests a new drug called 626 for people with systemic lupus erythematosus (SLE). It aims to see if the drug is safe and effective at reducing disease activity.
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
This trial tests two biologic drugs (belimumab or telitacicept) compared to a standard treatment (mycophenolate mofetil) for people with active lupus nephritis. The goal is to see if biologics work better at controlling kidney inflammation over 6 months.
This study tests an investigational drug called ACE1831 for people with active systemic lupus erythematosus (lupus) whose disease has not improved with usual treatments. The goal is to see if ACE1831 can reduce lupus activity and help control symptoms.
This study tests a new medicine (called GB261) given as an infusion for people with systemicsclerosis (scleroderma) that affects the skin widely. The goal is to see if it can reduce skin thickening and improve symptoms.
Hear when a new Systemic Lupus Erythematosus (SLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.